Pharmacokinetics of Ampicillin/Sulbactam in Critically Ill Patients with Acute Kidney Injury undergoing Extended Dialysis | Zendy

Johan M. Lorenzen | Zendy; Michael Broll | Zendy; Volkhard Kaever | Zendy; Heike Burhenne | Zendy; Carsten Hafer | Zendy; Christian Clajus | Zendy; Wolfgang Knitsch | Zendy; Olaf Burkhardt | Zendy; Jan T. Kielstein | Zendy

Open Access

Pharmacokinetics of Ampicillin/Sulbactam in Critically Ill Patients with Acute Kidney Injury undergoing Extended Dialysis

Author(s) -

Johan M. Lorenzen,

Michael Broll,

Volkhard Kaever,

Heike Burhenne,

Carsten Hafer,

Christian Clajus,

Wolfgang Knitsch,

Olaf Burkhardt,

Jan T. Kielstein

Publication year - 2012

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.05690611

Subject(s) - medicine , sulbactam , ampicillin , pharmacokinetics , dialysis , hemodialysis , dosing , intensive care , acute kidney injury , anesthesia , antibiotics , intensive care medicine , microbiology and biotechnology , biology , antibiotic resistance , imipenem

The fixed antibacterial combination of ampicillin and sulbactam is frequently used for various infections. Intact kidneys eliminate approximately 71% of ampicillin and 78% of sulbactam. Patients on thrice-weekly low-flux hemodialysis exhibit an ampicillin t(1/2) of 2.3 hours on and 17.4 hours off dialysis. Despite its frequent use in intensive care units, there are no available dosing recommendations for patients with AKI undergoing renal replacement therapy. The aims of this study were to evaluate the pharmacokinetics of ampicillin/sulbactam in critically ill patients with AKI undergoing extended dialysis (ED) and to establish a dosing recommendation for this treatment method.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research